News for 'Pharma'

Stock Market Today Feb 26, 2026: Sensex, Nifty End Mixed In Volatile Trade

Stock Market Today Feb 26, 2026: Sensex, Nifty End Mixed In Volatile Trade

Rediff.com26 Feb 2026

Indian equity markets experienced a volatile trading day, with the Sensex and Nifty closing almost flat. Market sentiment was influenced by global cues, US-Iran talks, and profit-booking activities.

Sensex surged 2,073 points at close, Nifty ended at 25,728

Sensex surged 2,073 points at close, Nifty ended at 25,728

Rediff.com3 Feb 2026

Stock market benchmark indices Sensex and Nifty ended 2.5 per cent higher on Tuesday after India and the US agreed to a trade deal under which Washington will bring down the reciprocal tariff on Indian goods to 18 per cent.

Oscar Fever Kickstarts On OTT This Week

Oscar Fever Kickstarts On OTT This Week

Rediff.com27 Feb 2026

The Oscar fever kickstarts with this week's OTT menu. Take your pick from Sukanya Verma's eclectic menu.

Indian pharma firms not copying products of Swiss cos: Goyal

Indian pharma firms not copying products of Swiss cos: Goyal

Rediff.com10 Jun 2025

Dismissing allegations that Indian phacosrmaceutical companies copy products of Swiss firms, Commerce and Industry Minister Piyush Goyal on Tuesday said it is a long-standing myth and India respects intellectual property rights and never steals technology from others. He said that Swiss pharmaceutical companies have not shown even a single instance that Indian companies have illegally copied any of their trademarks or patents or copyrighted technology.

How stock markets will fare on this Budget Day

How stock markets will fare on this Budget Day

Rediff.com1 Feb 2026

Bharat Electronics, Power Grid, NTPC and HDFC Bank were among the other major gainers. However, Infosys, Tata Steel, Eternal and Tech Mahindra were among the laggards.

Weak guidance may hit Sun Pharma in FY26

Weak guidance may hit Sun Pharma in FY26

Rediff.com1 Jun 2025

Despite a healthy performance in the fourth quarter of 2024-25 (Q4FY25), the stock of India's largest listed pharma company, Sun Pharmaceutical Industries (Sun Pharma), was under pressure on Friday due to a muted guidance. The company has guided for a high single-digit revenue growth for FY26, which is below what the Street was working with.

Will MBA In Dubai Earn Over Rs 18 LPA?

Will MBA In Dubai Earn Over Rs 18 LPA?

Rediff.com4 Feb 2026

rediffGURU Patrick D'souza, CAT expert and founder of Patrick100 explains how to pick a management course and college that will boost your career.

10 Stocks That May Gain From Budget

10 Stocks That May Gain From Budget

Rediff.com4 Feb 2026

The fiscal tilt towards capex benefits companies in investment-related sectors like capital goods, defence equipment, engineering & construction and metal & mining. The planned cut in revenue expenditure will weigh on companies in consumption sectors like FMCG, consumer durables and retail.

Sensex reclaims 84K-mark; Nifty ends up 174 points

Sensex reclaims 84K-mark; Nifty ends up 174 points

Rediff.com9 Feb 2026

Benchmark equity indices Sensex and Nifty extended their gains for the second straight session on Monday, driven by optimism over the India-US trade deal and robust buying in public sector banks, consumer durables, and realty stocks.

STT hike on Futures drags markets down; Sensex crashes 1,547 points

STT hike on Futures drags markets down; Sensex crashes 1,547 points

Rediff.com1 Feb 2026

Benchmark stock indices Sensex and Nifty dived sharply by nearly 2 per cent on Sunday after Finance Minister Nirmala Sitharaman proposed a hike in the Securities Transaction Tax (STT) on derivatives. Reversing the early gains, the 30-share BSE Sensex plunged sharply by 2,370.36 points or 2.88 per cent to slide below the 80,000-mark at 79,899.42 in afternoon trade as the finance minister announced a hike in STT on futures contracts to 0.05 per cent from the current 0.02 per cent.

Why The Markets Fell After 12.10 PM

Why The Markets Fell After 12.10 PM

Rediff.com1 Feb 2026

Ambareesh Baliga's quick take on the markets after the increase in STT on futures and options trading...

Budget 2026 boosts healthcare spend, drugs relief

Budget 2026 boosts healthcare spend, drugs relief

Rediff.com1 Feb 2026

The government on Sunday gave a strong push to upgradation and expansion of healthcare infrastructure, medical education and pharma sector with the Union Budget 2026-27 announcing a slew of steps, including those aimed at making India a global hub for allied healthcare professionals and biopharma manufacturing.

Indian pharma eyes US gains as $63.7 bn patent cliff nears

Indian pharma eyes US gains as $63.7 bn patent cliff nears

Rediff.com30 Jun 2025

The Indian pharmaceutical industry is likely to benefit from a major wave of patent expiries in the US, as small-molecule drugs worth $63.7 billion are expected to go off-patent between 2025-29, a 65 per cent rise over the previous five years, according to a report by Antique stock broking limited.

Coldrif syrup maker used industrial-grade materials: ED

Coldrif syrup maker used industrial-grade materials: ED

Rediff.com3 Dec 2025

An Enforcement Directorate (ED) probe has revealed that the manufacturer of Coldrif syrup, linked to the deaths of at least 20 children in Madhya Pradesh, used industrial-grade raw materials without quality checks. The investigation also found that Tamil Nadu Drugs Control Department officials were in frequent contact with the company but failed to conduct mandated inspections.

Sensex drops 245 points on persistent foreign fund outflows

Sensex drops 245 points on persistent foreign fund outflows

Rediff.com14 Jan 2026

From the 30-Sensex firms, Tata Consultancy Services, Asian Paints, Maruti, Sun Pharma, Hindustan Unilever, ICICI Bank, Kotak Mahindra Bank, Tech Mahindra, HDFC Bank and Larsen & Toubro were among the biggest laggards. On the other hand, Tata Steel, NTPC, Axis Bank and UltraTech Cement were among the gainers.

Sensex rises 317 pts on gains in auto, pharma shares

Sensex rises 317 pts on gains in auto, pharma shares

Rediff.com15 Jul 2025

Stock markets snapped the four-day falling streak on Tuesday with the benchmark Sensex rebounding by 317 points on buying in auto and pharma shares amid a decline in retail inflation to a more than six-year low, nearing the RBI's comfort zone. The 30-share BSE Sensex climbed 317.45 points or 0.39 per cent to settle at 82,570.91. During the day, it jumped 490.16 points or 0.59 per cent to 82,743.62. The 50-share NSE Nifty edged higher by 113.50 points or 0.45 per cent to 25,195.80.

Budget 2026 is cautious and also focussed on the long-term journey

Budget 2026 is cautious and also focussed on the long-term journey

Rediff.com10 Feb 2026

This year's Economic Survey and the Union Budget were more closely followed for more reasons than one.

What India gives, and what it gets: Highlights of India-US interim trade deal

What India gives, and what it gets: Highlights of India-US interim trade deal

Rediff.com7 Feb 2026

Both countries commit to provide each other preferential market access in sectors of respective interest on a sustained basis

Market Guru: 'This Is About Capital Preservation'

Market Guru: 'This Is About Capital Preservation'

Rediff.com18 Feb 2026

'The problem is not just slower growth, but also the quality of growth.'

Sensex jumps 487 points on optimism over India-EU FTA

Sensex jumps 487 points on optimism over India-EU FTA

Rediff.com28 Jan 2026

From the 30-Sensex firms, Bharat Electronics surged nearly 9 per cent post its December quarter earnings. Eternal, Bajaj Finance, Power Grid, Trent, Mahindra & Mahindra and UltraTech Cement were the other major gainers. Maruti, Sun Pharma, Infosys and Bharti Airtel were among the other laggards.

India, US to sign interim trade deal in March: Goyal

India, US to sign interim trade deal in March: Goyal

Rediff.com20 Feb 2026

Commerce and Industry Minister Piyush Goyal announced that an interim trade agreement between India and the US is likely to be signed in March and operationalised in April, with chief negotiators meeting in Washington to finalize the details.

Sensex climbs 304 pts on buying in metal, auto and pharma shares

Sensex climbs 304 pts on buying in metal, auto and pharma shares

Rediff.com13 Aug 2025

Among Sensex firms, Bharat Electronics, Eternal, Mahindra & Mahindra, Kotak Mahindra Bank, Tata Motors and Power Grid were the gainers. However, Adani Ports, ITC, UltraTech Cement and Titan were among the laggards.

Sensex slips 43 pts; IT shares fall on profit-taking

Sensex slips 43 pts; IT shares fall on profit-taking

Rediff.com23 Dec 2025

Among Sensex firms, Infosys, Bharti Airtel, Adani Ports, Sun Pharma, Tech Mahindra, Eternal, Axis Bank and Maruti were the major laggards. However, ITC, UltraTech Cement, Tata Steel and HDFC Bank were among the gainers.

Sensex tanks over 1,000 points, Nifty tumble over 1%

Sensex tanks over 1,000 points, Nifty tumble over 1%

Rediff.com20 Jan 2026

From the 30-Sensex firms, Eternal declined by 4.02 per cent, followed by Bajaj Finance (3.88 per cent), Sun Pharma, InterGlobe Aviation, Trent, Asian Paints, Mahindra & Mahindra and Bajaj Finserv. HDFC Bank emerged as the only gainer from the pack.

Investors lost Rs 9.40 lakh cr in Budget Sunday crash

Investors lost Rs 9.40 lakh cr in Budget Sunday crash

Rediff.com1 Feb 2026

The market capitalisation of BSE-listed companies eroded by Rs 9,40,581.75 crore to Rs 4,50,61,658.60 crore (USD 4.90 trillion) in a single day.

Mankind Pharma Targets Anti-Obesity Drug

Mankind Pharma Targets Anti-Obesity Drug

Rediff.com6 Mar 2025

'Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.'

Sun Pharma stock up 2.15% as US court clears alopecia drug launch

Sun Pharma stock up 2.15% as US court clears alopecia drug launch

Rediff.com12 Apr 2025

Sun Pharmaceutical Industries stock ended 2.15 per cent higher on Friday after zooming by almost 5 per cent in the morning trade on the back of an announcement that a court ruling has cleared the deck for the India's largest pharmaceutical company to launch its alopecia drug Leqselvi in the United States.

Stock markets end higher on rally in Infosys shares

Stock markets end higher on rally in Infosys shares

Rediff.com16 Jan 2026

Tech Mahindra, HCL Tech, State Bank of India, UltraTech Cement and HDFC Bank were also among the gainers. In contrast, Eternal, Asian Paints, Bharat Electronics, Sun Pharma and Maruti were among the laggards.

Cough syrup deaths: Pharma co to face criminal action

Cough syrup deaths: Pharma co to face criminal action

Rediff.com8 Oct 2025

Tamil Nadu Government will take criminal action against a drug manufacturer, whose cough syrup has been banned in the wake of children's deaths in Madhya Pradesh, state minister Ma Subramanian said here on Wednesday.

Trump slaps 100% tariffs on imported pharma products

Trump slaps 100% tariffs on imported pharma products

Rediff.com26 Sep 2025

United States President Donald Trump on Friday announced that his administration will impose a 100 per cent tariff on branded and patented pharmaceutical products beginning October 1, 2025, unless the manufacturing companies are building production facilities in the US.

Centre mandates blue strip on antimicrobial drugs to curb overuse

Centre mandates blue strip on antimicrobial drugs to curb overuse

Rediff.com24 Jan 2026

The Union health ministry has issued draft rules to mandate a blue vertical strip on all antimicrobial drug labels, aiming to rein in over-the-counter misuse and tackle India's growing antimicrobial resistance (AMR) problem.

Sensex, Nifty tank nearly 1%

Sensex, Nifty tank nearly 1%

Rediff.com9 Jan 2026

From the 30-Sensex firms, NTPC, ICICI Bank, Adani Ports, Bharti Airtel, Sun Pharma and Bajaj Finance were among the biggest laggards. However, Asian Paints, HCL Tech, Bharat Electronics and Reliance Industries were among the gainers.

Sensex sheds 367 points on foreign fund outflows

Sensex sheds 367 points on foreign fund outflows

Rediff.com26 Dec 2025

From the 30-Sensex firms, Bajaj Finance, Asian Paints, HCL Tech, Tata Consultancy Services, Eternal and Sun Pharma were among the biggest laggards. However, Titan, NTPC, Axis Bank, UltraTech Cement, Reliance Industries and Hindustan Unilever were the gainers.

Sigachi Industries CEO held over Telangana plant blast

Sigachi Industries CEO held over Telangana plant blast

Rediff.com28 Dec 2025

A top executive of Sigachi Industries has been arrested in connection with the explosion at its pharma plant in Telangana in June, which resulted in 54 deaths.

Smallcap To Watch Out For In 2026

Smallcap To Watch Out For In 2026

Rediff.com4 Feb 2026

After two years of strong gains, smallcap stocks fell sharply in 2025, but the correction may be setting up opportunities for long-term investors.

Stock markets surge nearly 1% on last trading session of 2025

Stock markets surge nearly 1% on last trading session of 2025

Rediff.com31 Dec 2025

From the 30-Sensex firms, Tata Steel, Kotak Mahindra Bank, Reliance Industries, Axis Bank, Titan and Trent were among the biggest gainers. However, Tata Consultancy Services, Tech Mahindra, Infosys, Bajaj Finance and Sun Pharma, were the laggards.

Ambitious, futuristic: PM Modi lauds Sitharaman's 9th Budget

Ambitious, futuristic: PM Modi lauds Sitharaman's 9th Budget

Rediff.com1 Feb 2026

Reiterating Sitharaman's statement that this is a youth power budget, Modi emphasised that the provisions made in the budget will prepare leaders, innovators and creators across different sectors.

'Good night, Happy New Year': Maduro's 1st words after US capture

'Good night, Happy New Year': Maduro's 1st words after US capture

Rediff.com4 Jan 2026

The Venezuelan President and his wife Cilia Flores were earlier captured from Caracas after US President Donald Trump unilaterally sanctioned a military operation on Venezuelan soil.

Budget 2026: Time To Fix The Weak Link In R&D Ecosystem

Budget 2026: Time To Fix The Weak Link In R&D Ecosystem

Rediff.com31 Jan 2026

Restoring weighted tax deductions and adopting a petty patents regime can foster firm-level innovative activity critical for competitiveness, points out Nagesh Kumar.

Dr Reddy's profit down 14% on low Lenalidomide US sales

Dr Reddy's profit down 14% on low Lenalidomide US sales

Rediff.com22 Jan 2026

Pharma major Dr Reddy's Laboratories (DRL) reported a 14 per cent year-on-year (Y-o-Y) drop in consolidated net profit to Rs 1,210 crore in the December quarter of FY 2025-26 (Q3FY26) on low sales of cancer drug Lenalidomide in the North American market. The firm's revenue from operations grew to Rs 8,727 crore in Q3FY26, a 4.4 per cent Y-o-Y increase from Rs 8,357 crore recorded for the same quarter last year.